Pay in 4 interest-free payments of $6.77 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Kucinskas and colleagues leveraged tirzepatide, one of a new class of effective anti-obesity medications that target GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) receptors
Available GLP-1s include semaglutide (Ozempic/Wegovy active ingredient) and tirzepatide (Mounjaro/Zepbound active ingredient, also targets GIP receptors)
Methods Data were derived from the cohort of the study Childhood Health, Activity, and Motor Performance School Study Denmark (CHAMPS study DK) including 485 school children without metabolic syndrome
N., Clark, B
Critically, there is a 15-30% overlap between T2D and obesity populations globally, indicating millions are at high risk for disease progression
US$ 25.10
US$ 21.39
US$ 24.46
US$ 22.36
